[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
Scientific Discovery and the Future of Medicine
March 24/31, 2015

Harnessing RNA Interference for TherapyThe Silent Treatment

Author Affiliations
  • 1Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, Massachusetts
  • 2Department of Pediatrics, Harvard Medical School, Boston, Massachusetts
  • 3Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts
JAMA. 2015;313(12):1207-1208. doi:10.1001/jama.2015.1241

RNA interference (RNAi) is a ubiquitous pathway that regulates gene expression. It uses small, imperfectly paired, double-stranded RNAs approximately 21 nucleotides long, called microRNAs, that are processed from longer stem-loop transcripts.1 MicroRNAs are taken up by the cytoplasmic RNA-induced silencing complex (RISC), which removes 1 strand, leaving an unpaired strand that binds to messenger RNAs (mRNAs) with a partially complementary sequence. RISC suppresses the expression of bound mRNAs by accelerating their degradation and suppressing their translation into protein. MicroRNAs and the RNAi gene-silencing pathway were first discovered in the 1990s in plants, worms, and flies. In those organisms, microRNAs play an important role in regulating changes in gene expression that occur in development and in protection from viruses.

First Page Preview View Large
First page PDF preview
First page PDF preview
×